IONIS PHARMACEUTICALS INC — Director's Dealing 2018

Feb 1, 2018

SEC Form 4/A — Form 4/A

Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2018-02-01

Reporting Person: BENNETT C FRANK (SVP, Antisense Research)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-01	Common Stock	M	12500	$7.25	Acquired	31614	Direct
2018-02-01	Common Stock	S	12500	$52.5008	Disposed	19114	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-01	Employee Stock Option (right to buy)	$7.25	M	12500	Acquired	2019-01-02	Common Stock (12500)	Direct

Footnotes

F1: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.32 to $52.68, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.